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HIV-1 depends on many host factors for propaga-
tion. Other host factors, however, antagonize
HIV-1 and may have profound effects on viral acti-
vation. Curing HIV-1 requires the reduction of latent
viral reservoirs that remain in the face of antiretrovi-
ral therapy. Using orthologous genetic screens, we
identified bromodomain containing 4 (BRD4) as
a negative regulator of HIV-1 replication. Antago-
nism of BRD4, via RNA interference or with a small
molecule inhibitor, JQ1, both increased proviral
transcriptional elongation and alleviated HIV-1
latency in cell-line models. In multiple instances,
JQ1, when used in combination with the NF-kB
activators Prostratin or PHA, enhanced the in vitro
reactivation of latent HIV-1 in primary T cells. These
data are consistent with a model wherein BRD4
competes with the virus for HIV-1 dependency
factors (HDFs) and suggests that combinatorial
therapies that activate HDFs and antagonize HIV-1
competitive factors may be useful for curing HIV-1
infection.
INTRODUCTION
Elucidation of the host factors that modulate HIV-1 propagation
has been a long-term goal of the HIV research community
(Friedrich et al., 2011). In principle, this knowledge should allow
us to develop therapies that seek to eradicate this disease
(Choudhary and Margolis, 2011; Yang et al., 2009). Current
antiretroviral therapy (ART) aimed at inhibiting viral enzymatic
activities prevents HIV-1 replication and halts the virus’s
destruction of the host’s immune system. However, patients
develop viremia upon treatment interruption due to the reacti-
vation of latent HIV-1 proviruses, and long-term ART has
been associated with some adverse effects (Hakre et al.,
2012; Margolis, 2010; Siliciano and Greene, 2011). To cure
HIV-1, such latent reservoirs must be purged, the most prom-
ising strategy for this being viral activation performed in unison
with ART to prevent de novo infection (Archin et al., 2012;
Siliciano and Greene, 2011).CRESULTS
In an ongoing effort to saturate the HIV-1 dependency factory
(HDF) siRNA screen (Brass et al., 2008), we found that depletion
of the transcriptional regulator bromodomain containing 4
(BRD4) enhances HIV-1 infection with the use of either of two
orthologous large-scale siRNA libraries (Figures 1A and 1B).
BRD4 is a bromodomain protein that binds to acetylated
histones and recruits transcription elongation factor b (PTEF-b),
thereby increasing full-length mRNA expression (Jang et al.,
2005; Yang et al., 2005). The establishment and maintenance
of transcription of the HIV-1 genome is a critical step in the viral
life cycle (Karn, 2011; Ott et al., 2011). After initiating transcrip-
tion from the HIV-1 long terminal repeat (LTR), the host’s RNA
polymerase II complex pauses due to the influence of negative
elongation factors (NELF and DSIF); this inhibition is overcome
by the viral protein Tat, which binds to the viral mRNA’s TAR
element and recruits PTEF-b, leading to phosphorylation of
both the polymerase and the negative elongation factors, result-
ing in transcriptional elongation (Karn, 2011; Ott et al., 2011;
Zhang et al., 2007). Because the Tat/PTEF-b complex regulates
viral transcription in a feed-forward manner, subtle alterations in
the availability of either component strongly influence viral gene
expression and activation (Karn, 2011; Karn and Stoltzfus, 2012;
Ott et al., 2011). Of note, the majority of PTEF-b is associated
with either the host cell’s chromatin or its 7SK ribonucleoprotein
(RNP) complex. The inaccessibility of PTEF-b presents a formi-
dable barrier to viral activation that only Tat can overcome via
its relocation of PTEF-b to the TAR element (Karn and Stoltzfus,
2012). BRD4 had also been previously implicated in HIV-1
biology. In different publications BRD4 has been suggested to
be a positive or negative regulator of HIV-1 gene expression
(Yang et al., 2005; Zhou et al., 2009). High level overproduction
of a C-terminal portion of BRD4 has been observed to inhibit
HIV-1 infection and compete with Tat for binding to PTEF-b
in vitro (Bisgrove et al., 2007; Urano et al., 2008). The latter
data suggest that BRD4 is necessary for basal viral transcription
but might compete with Tat during active viral transcription
(Bisgrove et al., 2007; Ott et al., 2011; Schro¨der et al., 2012).
Together with our loss-of-function data, these studies prompted
us to further investigate BRD4’s role in the viral life cycle and, in
particular, evaluate it as an antilatency target. To accomplish
this, we individually transfected three unique siRNAs against
BRD4 and monitored their effect on HIV-1 infection and theell Reports 2, 807–816, October 25, 2012 ª2012 The Authors 807
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Figure 1. BRD4 Depletion or Inhibition Increases HIV-1 Replication
(A and B) The results of the indicated RNAi library screens with the siRNA pools ranked in order of average relative fold infection, from lowest to highest. The
positions of known HDFs as well as the HIV-1-competitive factor (HCF), BRD4, from the screen are indicated. (A) Ambion Library. (B) esiRNA Library.
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depletion of BRD4 mRNA levels (Figures 1C and 1D). Similar
experiments were performed with the use of a diverse pool of
siRNAs against BRD4, esiRNAs. In all cases the level of HIV-1
infection correlated with the levels of BRD4 depletion, suggest-
ing that the effect on HIV-1 was attributable to the siRNA-
mediated targeting of BRD4. We did routinely observe a greater
difference in p24 staining in part II as compared to part I of these
assays (Figure 1D), andwe believe this may reflect the limitations
of the image analysis for detecting absolute levels of p24, in
addition to the potential of a nonlinear relationship existing
between p24 levels detected in part I and percentage of infection
scored in part II. Two out of three short hairpin RNAs (shRNAs)
against BRD4 also increased HIV-1 infection in a T cell line in
accordance with their depletion levels (Figures 1E and 1F).
Importantly, we also detected higher levels of HIV-1 infection in
primary human CD4+ T cells after BRD4 depletion (Figures 1G
and 1H). We then tested a small molecule, JQ1, which prevents
BRD4-mediated transcriptional enhancement by interfering with
its binding to acetylated histones (Delmore et al., 2011; Filippa-
kopoulos et al., 2010). Consistent with BRD4’s inhibiting HIV-1
infection and in keeping with a recent report (Banerjee et al.,
2012), we found that JQ1 increased the replication of HIV-1
both in HeLa cells and in a T cell line (Figures 1I, 1J, and S1A)
and that JQ1’s proviral effect was dependent on the presence
of BRD4 (Figure S1B).
We then investigated the mechanism of BRD4’s inhibition of
HIV-1. On the basis of previous studies and our observed effect
of JQ1 on pseudotyped viruses (Figures 1E and 1G), we
reasoned that inhibition of BRD4 may potentiate proviral
transcription. In support of this notion, the depletion of BRD4
specifically increased the infection of HIV-1 proviruses in com-
parison to its effect on a g-retrovirus (Moloney leukemia virus,
MLV; Figure 2A). BRD4’s loss also stimulated a stably integrated
Tat-dependent reporter gene whose expression is driven by
HIV-1’s LTR, in contrast to the effect seen with CMV-promoter-
dependent gene expression (Figure 2B). Similarly, the BRD4
inhibitor, JQ1, preferentially increased green fluorescent protein
(GFP) expression from an HIV-1 LTR when compared to an MLV
LTR (Figure 2C; Delmore et al., 2011; Filippakopoulos et al.,
2010). Moreover, neither AP-1- nor NF-kB-dependent reporters
were activated by JQ1 (Figure S2A). JQ1’s enhancement of
LTR activity was predominantly seen to be both Tat and TAR(C) HeLa MAGI cells were transfected with the indicated siRNAs for 72 hr, then i
transferred to a newplate of HeLaMAGI cells for 48 hr (part II). Part I and II cellswer
siRNA (Con). Identically transfected cellswere assessed for BRD4mRNAknockdo
(D) Cells were treated as in (C) but were transfected with esiRNA pools as indicat
control pool. Identically transfected cells were assessed for BRD4 mRNA knoc
esiRNA pool (right).
(E) Jurkat T cells were stably transduced with the indicated shRNAs, then infec
GFP-positive cells was determined by flow cytometry and the relative fold infect
(F) Western blot for cells in (E). kDa, kilodaltons.
(G) Primary human CD4+ T cells were stably transduced with the indicated shR
percentage of GFP-positive cells was determined by flow cytometry and the rela
(H) Western blot for cells in (G). The levels of a nonspecific band (loading) show
(I) HeLa MAGI cells were treated with either DMSO or JQ1 (500 nM) for 1 hr, the
(J) Jurkat T cells were treated with either DMSO or JQ1 (500 nM) for 1 hr, then infe
(M.O.I). After 48 hr the percentage of GFP-positive cells was determined by flow
Values represent the mean ± SEM; n > 3 throughout; *p < 0.05, **p < 0.01. Resu
Cdependent, suggesting that modulation of PTEF-b levels under-
lies the small molecule’s effects (Figures 2D, 2E, and S2B). In
studies using a T cell line stably expressing an HIV-1 LTR-GFP
reporter gene we observed that the area under the GFP expres-
sion curve for cells stably expressing Tat and treated with JQ1
was 3.3-fold greater than that seen with Tat and DMSO, the
percentage of GFP-positive cells increasing from 39% with Tat
and DMSO to 54% with Tat and JQ1. Altogether, these data
suggest that JQ1 in combination with Tat resulted in more cells
reactivating latent viruses and doing so with greater magnitude.
However, we did note a more modest stimulation of the HIV-LTR
reporter in the absence of Tat (Figures 2D and 2E), and this was
found to be TAR independent as well (Figure 2E). Consistent with
the assumption that JQ1 enhanced the available levels of
PTEF-b, we found that JQ1 treatment increased the association
of Tat with PTEF-b (Figure 2F). Notably, JQ1 improved poly-
merase processivity along HIV-1 proviruses and increased all
lengths of viral messenger RNAs (vmRNAs) tested (initial and
elongated vmRNAs), the most substantial enhancement being
seen for full-length vmRNAs (Figure 2G). Given the known inter-
actions of both BRD4 and Tat with PTEF-b (Bisgrove et al., 2007),
these data suggest amodel wherein BRD4 competes with Tat for
the localization of a limiting amount of PTEF-b and, therefore,
upon BRD4’s loss and/or chemical inhibition, more PTEF-b can
bind to Tat and stimulate proviral transcriptional elongation.
Since the depletion or inhibition of BRD4 results in the produc-
tion of 2- to 3-fold or greater viral gene expression, this suggests
that a significant amount of proviruses, 50% to 75%, are not
fully active. Thesequiescent virusesare reminiscent of latentprovi-
ruses present in HIV-1-infected individuals on long-term ART. To
explore this similarity, we investigatedBRD4’s contribution to viral
latency. Depletion of BRD4 in a promonocyte latency model, U1
cells, strongly increased both gag vmRNA expression and tran-
scriptional processivity (Figures 3A–3C; Folks et al., 1987; Pomer-
antz et al., 1990). Chemical inhibition of BRD4 by JQ1 also
enhanced transcriptional elongation in U1 cells (Figure 3D). U1
cells are impaired for vmRNA transcription because they express
Tat containing apointmutation that reduces transcriptional activa-
tion (Cannonetal., 1994; Emiliani et al., 1998). Incontrast,whenwe
decreasedBRD4 inanother latencycell line,ACH2,whichcontains
a proviruswith amutant TAR, we sawmoremoderate increases in
vmRNAproductionascomparedtothatof theU1cells (FigureS3A;nfected with HIV-IIIB (part I). Forty-eight hours later, the viral supernatant was
e stained for p24. Relative fold infection is normalized to the nontargeting control
wn through quantitative PCR (qPCR) and normalized to the control siRNA (right).
ed. Values were normalized to the nontargeting firefly luciferase (FLuc) esiRNA
kdown through quantitative PCR (qPCR) and normalized to the control FLuc
ted with VSV-G NL4-3-GFP HIV-1. At 72 hr after infection, the percentage of
ion normalized to the shFLuc-expressing control line.
NAs, then infected with VSV-G NL4-3-GFP HIV-1. At 72 hr after infection, the
tive fold infection normalized to the shFLuc-expressing control line.
relative protein loading.
n infected with HIV-IIIB as in (C).
cted with VSV-G NL4-3-GFP HIV-1 using the indicated multiplicity of infections
cytometry.
lts were analyzed by unpaired t tests. See also Figure S1.
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Figure 2. BRD4 Inhibition Stimulates HIV-1 Gene Expression and Increases Tat-Dependent Transcriptional Elongation and Tat-PTEF-b
Association
(A) HeLa-T4 cells were transfected with the indicated siRNAs for 72 hr, then infected with either VSV-G HIV-YFP (HIV) or VSV-G MLV-GFP (MLV). After 48 hr the
percentage of YFP of GFP positive cells was determined and normalized to the control siRNA.
(B) HeLa-Tat-III cells stably expressing either an LTR- or a CMV-driven d1-EGFP reporter gene were transfected with the indicated siRNAs. After 48 hr, GFP
positive cells were measured and normalized to the control siRNA.
(C) HeLa-T4 cells stably transduced with a HIV-1 LTR-GFP reporter (LTR-GFP) or an MLV LTR-GFP reporter (MLV-GFP) were treated with the indicated
concentrations of JQ1 for 48 hr, after which the relative fold infection was determined by the imaging of GFP-positive cells and cell nuclei (DNA stained).
(D) Jurkat T cells stably expressing an HIV-1 LTR-GFP reporter gene (LTRG cells) were transduced with gamma retroviruses expressing either Tat or the empty
vector alone (vector). At 48 hr after transduction, cells were treated with DMSO or JQ1 (500 nM); 48 hr later the number of GFP expressing cells (GFP) was
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Cannon et al., 1994; Emiliani et al., 1996). This is consistent with
BRD4 antagonizing Tat’s recruitment of PTEF-b.
Overcoming insufficient transcription is important for acti-
vating latent HIV-1 (Dahl and Palmer, 2009; Karn and Stoltzfus,
2012). Therefore, given JQ1’s effect on transcriptional elonga-
tion, we evaluated its impact on latent HIV-1 when paired with
compounds that boost transcriptional initiation by stimulating
HDFs (HDF activators). Two such HDF activators are the natural
product, Prostratin (12-deoxyphorbol 13-acetate; Gulakowski
et al., 1997; Williams et al., 2004), and the cytokine, TNF-a
(Duh et al., 1989; Folks et al., 1987), both of which stimulate the
HDF, NF-kB, a transcription factor that is essential for HIV-1 LTR
activity (Chan and Greene, 2012; Williams et al., 2004). Interest-
ingly, whenwe tested JQ1 together with Prostratin in U1 cells, we
discovered that this combined treatment synergistically
increased latent viral gene expression >100-fold, most likely by
enhancing both transcriptional initiation and elongation (Fig-
ure 3E; Barboric et al., 2001; Chan and Greene, 2012). Using
several T cell J-Lat cell lines (Jordan et al., 2003), we observed
increased HIV-1 LTR expression when using JQ1 and Prostratin
in combination (Figures 3F and S3C). In addition, we found that
stimulation of HIV-1 reporter gene expression in J-Lat T cell lines
by either TNF-a or PMA was also enhanced by JQ1 (Figures 3G
and 3H). It is unclear why these clonal lines do not achieve full
activation under these conditions, but possible explanations
include cell-to-cell variability and genetic drift. We note, how-
ever, that JQ1 alone had less effect in the J-Lat T cell lines as
compared to the other cells tested, perhaps reflecting cell-line-
specific activation states or requirements. In addition, when we
evaluated JQ1 together with another latent HIV-1 activator,
SAHA (suberoylanilide hydroxamic acid), a bifunctional cell-
differentiating agent and nonspecific histone deacetylase inhib-
itor, we saw a modest improvement in HIV-1 gene expression in
the J-Lat cell line A2 as compared to JQ1 treatment alone (Fig-
ure S3D; Archin et al., 2009; Richon et al., 1998).
On the basis of the enhanced viral activation produced by JQ1
alone or together with the HDF activators in the cell-line-latency
models, we then tested these molecules in the setting of newly
infected primary human T cells. Peripheral blood mononucleo-
cytes (PBMCs) from uninfected volunteers were isolated, then
either selected for CD4+ expression (donors 1–4) or depleted of
CD8+ T cells (donors 5 and 6). The cells were stimulated with
plate-bound CD3 and CD28 antibodies together with IL-2.
Pretreatment of these activated T cells with JQ1 together withassessed by flow cytometry. The percentage of GFP-positive cells was as follow
0.0750%. The mean of GFP intensity was calculated for all sorted cells. Data are
(E) 293T cells were transfected with the indicated combinations of plasmids and
(dTAR) HIV-1 LTR-luciferase reporter vectors, as well as a HIV-1 Tat expression v
performed at 48 hr after transfection, and the relative light units (RLU) were norma
and empty vector plasmids.
(F) HeLa cells stably transduced with a FLAG-Tat were incubated with JQ1 (500
cipitation using anti-FLAG antibodies. An anti-CDK9 antibody was used to detec
FLAG-Tat level.
(G) Jurkat T cells were treated with JQ1 (500 nM) or DMSO for 1 hr, then infecte
length assessed with the use of the indicated primers. Initiation: 10–59 bp. Elonga
2341–2433 bp), numbers denoting the amplification region of the NL4-3 HIV-1 tran
the DMSO control.
Values represent the mean ± SEM; n > 3 throughout; *p < 0.05, **p < 0.01. Resu
Ceither PMA (donors 1 and 2) or Prostratin (donors 3–6) led to
substantial increases inHIV-1-encoded reporter geneexpression
in all cases (Figure 4A). Interestingly, under these conditions, JQ1
alone had little to no effect on HIV-1 gene expression, similar to
what was seen with the J-Lat T cell lines.
To explore the ability of JQ1 to both reactivate and stimulate
the replication of HIV-1 within latently infected cells, we tested
its effect on human CD4 T cells isolated from 19 ART-treated
patients, all of whom had achieved durable viral suppression
(plasma HIV RNA levels < 75 copies/ml) for a minimum of
52 weeks (Table S1). During analysis, patients had a median
period of stable viral suppression of 226 weeks (interquartile
range 149–390 weeks) and a median CD4+ T cell count of
698 cells/mm3 (interquartile range 595–1027). Cryopreserved
PBMCs were rested for 3 days in media containing Nevaripine
to prevent viral infection (600 nM), then washed and stimulated
with Prostratin (250 nM), Phytohaemagglutinin (PHA, 2 mg/mL),
or SAHA (500 nM) for 6–48 hr (see Experimental Procedures) in
the presence or absence of JQ1 (250 nM).
Treatment with Prostratin, PHA, or SAHA resulted in detect-
able HIV replication in 12 of 19 patient samples (Table S2). Of
these 12 samples, seven showed enhanced viral replication
when JQ1 treatment was used in combination with either Pros-
tratin or PHA (Figures 4B and 4E), with three of the seven patient
samples having a negligible response to Prostratin or PHA treat-
ment in the absence of JQ1 (donors 1, 3, and 11). Interestingly,
JQ1 also inhibited the viral replication induced by either Prostra-
tin or PHA in five patient samples in the absence of cytotoxicity
(Figures 4C–4E, S4A, and S4B). Indeed, in two instances, treat-
ment with JQ1 enhanced HIV-1 reactivation with one compound
(either Prostratin or PHA) while inhibiting reactivation by the other
(donors 3 and 9). A 6 hr treatment with SAHA reactivated latent
HIV-1 in three samples (donors 2, 5, and 7; Table S2), but in
each instance JQ1’s addition suppressed SAHA’s effect. In
summary, we found that a heterogeneic response to latent
HIV-1 reactivation occurs in T cells from different donors and
that in multiple instances JQ1 could augment or synergize with
Prostratin or PHA to reactivate latent viruses.
Tat-mediated transcription serves as a critical regulator of
HIV-1 activation (Karn and Stoltzfus, 2012; Ott et al., 2011).
Our data support the notion that PTEF-b levels are rate limiting
for HIV-1’s transcription in both transformed and primary cells
(Isel and Karn, 1999; Kao et al., 1987). In this model, latent
HIV-1 (Figure 4F, top panel) is initially reactivated by the bindings: JQ1+Tat, 54.1%; DMSO+Tat, 39.0%; JQ1+vector, 0.335%; DMSO+vector,
representative of three independent experiments.
treated with JQ1 (500 nM) or DMSO for 24 hr: wild-type (WT) or TAR-deleted
ector (Tat) or the matching empty vector (vector). A dual luciferase assay was
lized to the DMSO-treated cells transfected with the WT HIV-1 LTR-luciferase
nM) or DMSO for 24 hr. Cells were then lysed and subjected to immunopre-
t the endogenous CDK9 levels. An anti-FLAG antibody was used to detect the
d with VSV-G NL43-GFP HIV-1. After 48 hr cDNA was prepared and vmRNA
tion: proximal (Pro, 29–180 bp), intermediate (Int, 836–1015 bp), and distal (Dis,
script as determined from the transcriptional start site. Data were normalized to
lts were analyzed by unpaired t tests. See also Figures S1 and S2.
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Figure 3. BRD4 Inhibition Alleviates HIV-1 Latency
(A) U1 cells were stably transduced with the indicated shRNAs, then HIV-1 gag mRNA levels were measured by qPCR and normalized to the shFLuc control.
(B) Western blot of cells in (A).
(C) A transcriptional elongation assay was performed as above using cells in (A). The level of transcripts was normalized to the shFLuc control. Note log scale on
the y axis.
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of transcription factors (i.e., NF-kB) to the LTR (middle panel).
This early event produces sufficient Tat to recruit the limited
amount of free PTEF-b, the majority of which is sequestered
on chromatin by BRD4. Upon inhibition or depletion of BRD4,
additional PTEF-b is released and can interact with Tat, thereby
producing maximal transcription (stimulated reactivation,
bottom panel). This PTEF-b-dependent stimulation is most
significant when BRD4 is inhibited under conditions of high level
LTR activity (Prostratin, PMA, PHA, or TNF-a), which increases
transcriptional initiation and elevated Tat levels. On the basis of
the increase in viral replication that occurs when NF-kB is acti-
vated and BRD4 is inhibited, our data demonstrate that in
some instances the pairing of JQ1 with HDF-activators more
effectively alleviates latency.
DISCUSSION
Beginning with orthologous large-scale genetic screening for
host factors that modulate HIV-1 replication in vitro, we discov-
ered that depletion of BRD4 increased viral replication in trans-
formed cells and enhanced HIV infection in primary human
CD4+ T cells. This work significantly extends elegant previous
studies demonstrating that BRD4 modulates HIV-1 infection
(Bisgrove et al., 2007; Urano et al., 2008). Indeed, we now
show that BRD4’s depletion or inhibition stimulated viral gene
expression from both newly integrated and latent proviruses.
Furthermore, we revealed that BRD4’s loss enhanced HIV-1
gene expression by increasing Tat/PTEF-b association and
host polymerase transcriptional elongation.
We found that in multiple instances a small molecule inhibitor
of BRD4, JQ1, when used in combination with the transcriptional
activators Prostratin or PHA, could trigger and/or markedly
enhance the in vitro reactivation of latent HIV-1 in primary human
T cells, thereby identifying a new first-in-class antilatency small
molecule. While this manuscript was in preparation, Banerjee
et al. also reported that JQ1 alone could stimulate HIV-1 replica-
tion in a T cell line and in the primary T cells from one of three
patients receiving ART (Banerjee et al., 2012). Our study now
significantly extends those observations by providing mecha-
nistic insight into how BRD4, and thus JQ1, affect the HIV-1
life cycle. Importantly, we also describe how using JQ1 in
combination with compounds known to alleviate viral latency,
Prostratin or PHA, greatly increased reactivation of HIV-1 in
latently infected primary T cells from 7 of 19 patients on long-
term ART. Of note, our work shows that JQ1 alone does not
reactivate HIV-1 in latently infected primary T cells, which differs
from the single example of modest viral reactivation by JQ1(D) A transcriptional elongation assay was performed as above using U1 cells tre
normalized to the values of the DMSO-treated controls. Note log scale on the y
(E) U1 cells were treated with either JQ1 (500 nM) or Prostratin (1 uM) alon
mRNA determined.
(F) J-Lat A2 cells were treated with JQ1 (500 nM) or Prostratin (1 mM) for 72 hr. C
assays the relative luminescence units (RLU) of DMSO treated cells was set at 1
(G) The indicated J-Lat cell lines were treated with JQ1 (500 nM), PMA (200 nM), o
the percentage of positive cell was calculated.
(H) The indicated J-Lat cell lines were treated with the noted compounds (JQ1 (500
positive cells was determined by flow cytometry.
Values represent the mean +/ S.E.M., N > 3 throughout. *p < 0.05, **p < 0.01. R
Calone that was recently reported (Banerjee et al., 2012). Our
data instead reveal that JQ1 potentiates the actions of several
known transcriptional HIV-1 reactivating compounds, PMA,
PHA, TNF-a, and Prostratin. Therefore, in comparison, our
study demonstrates an enhanced potential for the use of agents
that improve transcriptional elongation (e.g., JQ1) in reactivating
latent HIV-1 reservoirs, via their pairing with small molecules
that mobilize LTR-enhancing HDFs (e.g., NF-kB). Furthermore,
by using such combinations to create synergies, it may be
possible to improve the efficacy and minimize the toxicity of
antilatency therapy (Choudhary and Margolis, 2011; Siliciano
andGreene, 2011). A commonmechanism of HIV-LTR activation
shared by these compounds is the stimulation of NF-kB. In
certain instances NF-kB’s activity is dependent on interaction
with BRD4 (Sharma et al., 2007). However Huang et al. deter-
mined that NF-kB transcriptionally activates a subset of
genes in a BRD4-independent manner, and our data are con-
sistent with the HIV-LTR being one such example (Huang
et al., 2009).
In contrast to data generated through the use of several trans-
formed cell lines or newly infected primary T cells, we observed
a marked heterogeneity in the ability of the tested compounds
to reactivate latent HIV-1 in primary T cells from patients on
long-term ART. We also noted that the addition of JQ1 along
with these HDF-activating compounds could either promote or
inhibit viral reactivation. While the dichotomous effects of JQ1
are likely attributable to many factors, insight may come from
earlier work showing that BRD4 is needed for basal HIV-1 LTR
transcription, suggesting that interfering with this early action
of BRD4 may prevent further increases in replication (Ott et al.,
2011); additional possibilities include cell-lineage-dependent
variations of BRD4 or PTEF-b expression or availability. Alto-
gether, these results suggest that it will be useful to carry out
personalized in vitro testing to identify efficacious combinations
of HIV-1 reactivators, including JQ1.
Our work also demonstrates that in addition to HDFs that are
needed by HIV-1 (Brass et al., 2008) and HIV-1 restriction factors
(HRFs) that have evolved to specifically inhibit the virus (Yan and
Chen, 2012), there exists a third functional class of host factors,
HIV-1 competitive factors (HCFs); i.e., BRD4. Such factors have
not been selected as being antiviral per se, but they can nonethe-
less blunt infections and promote latency by competing with
HIV-1 for limiting cellular resources; e.g., PTEF-b. It follows,
then, that antilatency strategiesmight be improved by combining
HDF-activating therapies together with small molecules that
transiently inactivate specific HRFs and/or HCFs. Because
HIV-1 latency exists via multiple mechanisms, we deem it likelyated with either JQ1 (500 nM) or DMSO for 48 hr. The level of transcripts was
axis.
e, or the combination. After 72 hr cDNA was prepared and levels of gag
ells were then assessed for GFP expression and viability. For the cell viability
00%.
r the both for 72 hr. GFP positive cells were assessed using flow cytometry, and
nM), TNF-a (10 ng/ml) alone or in combination. At 72 hr the percentage of GFP
esults were analyzed by unpaired t tests. See also Figure S3.
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Figure 4. BRD4 Inhibition in Combination with HIV-1 HDF Activators Enhances HIV-1 Replication in Primary Human T Cells, as well as HIV-1
Reactivation in Latently Infected T Cells from Patients on Long-Term ART
(A) Primary CD4+ T cells or PBMCs were isolated from HIV-1-negative donors and treated with the indicated compounds (JQ1, 500 nM; PMA, 200 nM; or
Prostratin, 1 mM) alone or with JQ1 and Prostratin combined for 1 hr, then infected with VSV-G NL4-3-GFP HIV-1. After 72 hr the number of GFP expressing cells
was determined by flow cytometry and normalized to the DMSO control.
(B–D) CD8-depleted PBMCs isolated from ART-treated patients were rested for 3 days in the presence of Nevaripine (600 nM), followed by reactivation with
DMSO or Prostratin (250 nM) for 48 hr in the presence or absence of JQ1 (250 nM). Viral replication was assessed by p24 ELISA on days 7, 14, and 21. Donors
were numbered according to whether JQ1 had a beneficial effect on Prostratin reactivation (B) or a nonbeneficial or inhibitory effect (C and D).
(E) Viral replication was assessed as described above, but reactivation was assessed with DMSO or PHA (2 mg/mL) in the presence or absence of JQ1 (250 nM)
for 48 hr.
(F) Model of BRD4 inhibition reactivating latent HIV-1 transcription. Latent HIV-1 (top panel) is initially reactivated by the binding of transcription factors
(e.g., NF-kB) to the LTR, resulting in the production of sufficient Tat to modestly compete for some of the PTEF-b complexed with chromatin-associated
BRD4 (acetylated histones) or 7SK-RNP (reactivation, middle panel). Upon antagonism of BRD4 by chemical inhibition with either JQ1 or RNAi, additional
PTEF-b is made available from the chromatin-sequestered pool, thus lowering the barrier for interaction with Tat and producing maximal proviral
transcription (stimulated reactivation, bottom panel). Enhanced viral transcription leads to the amplification of the feed-forward regulatory loop producing
higher levels of Tat that in turn recruit the now more readily available PTEF-b (denoted as more intensely colored Tat and PTEF-b components). RNA pol II,
RNA polymerase II; CTD = carboxy terminal domain of RNApol; AC, histone acetylation; NELF and DSIF, negative elongation factors removed after phos-
phorylation by PTEF-b.
See Figure S4 and Tables S1 and S2.that continuing to improve and integrate our basic understanding
of how host proteins modulate latency will provide additional
insights and, in doing so, help guide the way to a cure.
EXPERIMENTAL PROCEDURES
Small Molecules
Prostratin and SAHA were from Santa Cruz (sc-203422, sc-220139). and
PMA was from Sigma (P1585). Compounds were used at optimized concen-814 Cell Reports 2, 807–816, October 25, 2012 ª2012 The Authorstrations: JQ1 (500 nM), Prostratin (1 mM), PMA (200 nM), SAHA (0.5 mM). See
Extended Experimental Procedures for more details.Genetic Screening for HIV-1 Modulators Using Orthologous RNAi
Libraries
To identify host factors that modulate HIV-1 replication, we performed RNAi
screens by using two genome-wide siRNA resources (Silencer Select,
Ambion; Library 2, Mission esiRNAs, Sigma) and following a previously
described protocol (Brass et al., 2008).
siRNAs
BRD4 siRNAs and shRNAs were used. All siRNAs were used at a 50 nM final
concentration with the use of Oligofectamine transfection lipid (Invitrogen).
Study Subjects
HIV-infected adults and HIV-seronegative controls were recruited from
outpatient clinics at Massachusetts General Hospital and affiliated hospitals.
The respective institutional review boards approved this study, and all subjects
gave written consent for participation.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, four
figures, and two tables and can be found with this article online at http://dx.
doi.org/10.1016/j.celrep.2012.09.008.
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